Our mission is to research, develop, and deliver innovative medicines to improve and extend people’s lives with cancer.
MAIA Biotechnology, Inc. is a targeted therapy, immune-oncology company, focused on development of first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer.
Investigational drug candidates and research:
- THIO, a first-in-class telomere-by-telomerase targeting agent in clinical development for the treatment of multiple cancer types (read more about THIO)